EVIDENCE LIBRARY
Diazepam Appeared as an Inflammatory-Bowel-Disease Repurposing Candidate in Linked Data Analyses
A computational study combined adverse-event reports, claims, and gene-expression patterns to identify potential uses of existing medicines. Candidate selection was not proof of clinical efficacy.
A computational study combined adverse-event reports, claims, and gene-expression patterns to identify potential uses of existing medicines. Candidate selection was not proof of clinical efficacy.
How the signal was assembled
The investigators looked for inverse associations using adverse-event disproportionality and prescription-sequence analyses. Diazepam, haloperidol, and hydroxyzine emerged among possible inflammatory-bowel-disease candidates.
Gene-expression analyses added a proposed mechanistic rationale, including pathways relevant to cytokine signaling. These methods offered complementary forms of hypothesis-generating evidence.
Multiple signals do not remove confounding
Reporting practices, prescribing indications, healthcare use, and the limitations of claims can all shape inverse associations. A transcriptomic resemblance does not demonstrate a beneficial effect in a patient.
The study did not randomize diazepam treatment for bowel disease or establish an effective regimen. Its findings support candidate prioritization for further research. When describing the source, retain the distinction between a repurposing signal, a proposed pathway, and a treatment outcome rather than claiming diazepam prevents or treats inflammatory bowel disease.
Source paper
Original analysis of the supplied journal article, identified as PMC6177143.